VERZONI, ELENA
 Distribuzione geografica
Continente #
NA - Nord America 645
EU - Europa 613
AS - Asia 196
OC - Oceania 7
SA - Sud America 5
AF - Africa 2
Totale 1468
Nazione #
US - Stati Uniti d'America 637
GB - Regno Unito 357
CN - Cina 133
IT - Italia 118
DE - Germania 45
SE - Svezia 43
FI - Finlandia 25
KR - Corea 22
JP - Giappone 17
IN - India 8
AU - Australia 7
CA - Canada 6
UA - Ucraina 5
BR - Brasile 4
NL - Olanda 4
FR - Francia 3
TR - Turchia 3
AT - Austria 2
BE - Belgio 2
ES - Italia 2
GR - Grecia 2
MX - Messico 2
MY - Malesia 2
TW - Taiwan 2
VN - Vietnam 2
AR - Argentina 1
BG - Bulgaria 1
CH - Svizzera 1
DK - Danimarca 1
HK - Hong Kong 1
IL - Israele 1
IR - Iran 1
JO - Giordania 1
KE - Kenya 1
MD - Moldavia 1
NP - Nepal 1
PK - Pakistan 1
PL - Polonia 1
SG - Singapore 1
TN - Tunisia 1
Totale 1468
Città #
Southend 332
Fairfield 82
Milan 81
Wilmington 68
Seattle 67
Princeton 60
Ashburn 45
Houston 35
Woodbridge 34
Munich 33
Cambridge 31
Nanjing 30
Chandler 26
Dearborn 24
Beijing 21
Ann Arbor 13
Des Moines 12
Redwood City 12
Shenyang 8
Hangzhou 7
Hebei 7
London 7
Phoenix 7
Changsha 6
Jinan 6
Shanghai 6
Silver Spring 6
Tokyo 6
Zhengzhou 6
Chicago 5
Guangzhou 5
Jiaxing 5
San Diego 5
Toronto 5
Fremont 4
Los Angeles 4
Nanchang 4
Norwalk 4
Tianjin 4
Grafing 3
San Francisco 3
Seoul 3
São Paulo 3
Athens 2
Berlin 2
Fuzhou 2
Hanoi 2
Hefei 2
Herne 2
Kuala Lumpur 2
Medford 2
Rho 2
Rome 2
Sandwich 2
Taiyuan 2
Vienna 2
Akita 1
Amman 1
Amsterdam 1
Ankara 1
Arcadia 1
Arnhem 1
Barcelona 1
Boisbriand 1
Brooklyn 1
Brussels 1
Burlingame 1
Burwood 1
Central 1
Chisinau 1
Cleveland 1
Davis 1
Duncan 1
Farmington 1
Foggia 1
Gent 1
Haifa 1
Heidelberg 1
Helsinki 1
Huntington 1
Hyderabad 1
Jawalakhel 1
Köln 1
Maisons-Alfort 1
Mexico City 1
Mountain View 1
Muenster 1
Nairobi 1
Nashville 1
New York 1
Ningbo 1
Nishinotoindori 1
Nutley 1
Odense 1
Osaka 1
Pittsburgh 1
Pola De Lena 1
Redmond 1
Richmond 1
Roswell 1
Totale 1205
Nome #
Cabozantinib in the treatment of advanced renal cell carcinoma : Design, development, and potential place in the therapy 135
Butterfly and renal cell cancer : Out of chaos comes order 112
Targeted treatments in advanced renal cell carcinoma : focus on Axitinib 108
Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors 99
Clinical impact of Pancreatic metastases from renal cell carcinoma : A multicenter retrospective analysis 96
Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma? 93
Treatment of collecting duct carcinoma : current status and future perspectives 78
Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies : overall results from a large cohort of patients 67
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors : implications for clinical practice, trial design, and molecular interrogation 62
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma 61
Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases 50
From biology to clinical experience : evolution in the knowledge of neuroendocrine tumours 50
Safety profile and treatment response of everolimus in different solid tumors : an observational study 48
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma : results from a large cohort of patients 47
Study design and clinical evidence in mRCC : can we save axitinib as a first-line therapy? 46
Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors 45
Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents 45
Immunotherapy advances in uro-genital malignancies 42
Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer : a systematic review and meta-analysis 41
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma : a systematic review and meta-analysis of literature data 39
Management of advanced genitourinary tumors 38
Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib 37
First line treatment of metastatic renal cell carcinoma : two standards with different toxicity profile 36
Patient approach in advanced/metastatic renal cell carcinoma : focus on the elderly population and treatment-related toxicity 36
Prognostic role of pancreatic metastases from renal cell carcinoma : Results from an Italian center 34
Treatment of elderly patients with metastatic renal cell carcinoma 33
Targeted therapies and survival: What we can learn from studies in advanced renal cell carcinoma 30
Rationale and protocol of SOAP : A phase II study to evaluate the efficacy of Sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma 29
Biomarker-driven immunotherapy for precision medicine in prostate cancer 12
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) 7
Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients 3
Totale 1659
Categoria #
all - tutte 2036
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2036


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018242 049303 1130 1334 308295
2018/2019284 8428190 318 341 29202226
2019/2020303 46161131 1734 3224 38301113
2020/2021196 19161010 2524 911 3911814
2021/2022276 151287 912 1122 142912125
2022/202352 52000 00 00 0000
Totale 1659